Clinical Trial

A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

Study acronym: 8282-Reduced
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-05-16; most recent amendment 2026-03-10.
Status change: Not Yet Recruiting → Recruiting 2025-10-02
Trial Details
NCT Number NCT06979375
Lead Sponsor Novo Nordisk A/S
Conditions Heart Failure
Enrollment 200 participants
Start Date 2025-06-30
Primary Completion 2027-05-16 (estimated)
Study Completion 2028-01-23 (estimated)
Updated on ClinicalTrials.gov 2026-03-11